SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E Cariani, L Roli, G Missale, E Villa, C Ferrari, T Trenti, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis, The Pharmacogenomics Journal, 2015,

    CrossRef

  2. 2
    Yujia Li, Shilin Li, Xiaoqiong Duan, Bing Liu, Chunhui Yang, Peibin Zeng, Ian McGilvray, Limin Chen, Activation of endogenous type I IFN signaling contributes to persistent HCV infection, Reviews in Medical Virology, 2014, 24, 5
  3. 3
    Fasiha Kanwal, Donna L. White, Shahriar Tavakoli–Tabasi, Li Jiao, Derek Lin, David J. Ramsey, Andrew Spiegelman, Jill Kuzniarek, Hashem B. El–Serag, Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities, Clinical Gastroenterology and Hepatology, 2014, 12, 2, 327

    CrossRef

  4. 4
    José Antonio Carrión, Elena Gonzalez-Colominas, Montserrat García-Retortillo, Nuria Cañete, Isabel Cirera, Susanna Coll, Maria Dolors Giménez, Carmen Márquez, Victoria Martin-Escudero, Pere Castellví, Ricard Navinés, Juan Ramon Castaño, Josep Anton Galeras, Esther Salas, Felipe Bory, Rocío Martín-Santos, Ricard Solà, A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C, Journal of Hepatology, 2013, 59, 5, 926

    CrossRef

  5. 5
    Antonio D’Avolio, Amedeo De Nicolò, Danilo Agnesod, Marco Simiele, Adnan Mohamed Abdi, Sujan Dilly Penchala, Lucio Boglione, Giuseppe Cariti, Giovanni Di Perri, A UPLC–MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir, Journal of Pharmaceutical and Biomedical Analysis, 2013, 78-79, 217

    CrossRef

  6. 6
    Jennifer J. Kiser, James R. Burton, Gregory T. Everson, Drug–drug interactions during antiviral therapy for chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 10, 596

    CrossRef

  7. 7
    Robert Flisiak, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Emerging treatments for hepatitis C, Expert Opinion on Emerging Drugs, 2013, 18, 4, 461

    CrossRef

  8. 8
    Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba, Sustained and rapid virological responses in hepatitis C clinical trials, Clinical Investigation, 2013, 3, 11, 1083

    CrossRef

  9. 9
    Troels K H Scheel, Charles M Rice, Understanding the hepatitis C virus life cycle paves the way for highly effective therapies, Nature Medicine, 2013, 19, 7, 837

    CrossRef

  10. 10
    Paul J. Clark, Andrew J. Muir, Lost in translation? IL28B's discovery and the journey back to the patient, Hepatology, 2012, 56, 1
  11. 11
    Geoffrey W. McCaughan, New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting, Journal of Hepatology, 2012, 57, 6, 1361

    CrossRef

  12. 12
    David R Booth, Golo Ahlenstiel, Jacob George, Pharmacogenomics of hepatitis C infections: personalizing therapy, Genome Medicine, 2012, 4, 12, 99

    CrossRef